AtriCure stock (US04963C1099): Q1 revenue jumps 14% to $141M amid return to profit

AtriCure reported Q1 2026 revenue of $141.25 million, up 14% year-over-year, with a swing to net income of $0.108 million from prior loss. Shares fell 5.1% post-earnings.

AtriCure, Inc. (Nasdaq: ATRC) announced first-quarter 2026 results on May 14, 2026, posting revenue of US$141.25 million, a 14.2% increase from US$123.62 million in the prior-year period. The company swung to net income of US$0.108 million, compared to a net loss of US$6.75 million a year earlier, according to Simply Wall St as of May 14, 2026. Despite the improved financials, the stock dropped 5.1% following the release.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AtriCure, Inc.
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: United States, Asia-Pacific
• Key revenue drivers: Surgical ablation devices, left atrial appendage exclusion
• Home exchange/listing venue: Nasdaq (ATRC)
• Trading currency: USD

AtriCure: core business model

AtriCure develops, manufactures, and sells devices for surgical ablation of cardiac tissue, left atrial appendage exclusion, and peripheral nerve ablation for pain management. The company's products target medical centers primarily in the United States and Asia-Pacific regions. This focus positions AtriCure in the growing minimally invasive cardiac surgery market, relevant for US investors tracking medtech innovation amid rising atrial fibrillation treatments.

Main revenue and product drivers for AtriCure

Key products include the cryoSPHERE MAX, cryoXT, EnCompass, and AtriClip platforms. Management highlighted recent launches and growing adoption as drivers for double-digit revenue growth in Q1 2026 results published May 14, 2026, per Simply Wall St as of May 14, 2026. These devices support clinical investments boosting both top-line expansion and margins.

Industry trends and competitive position

The cardiac ablation device sector benefits from increasing prevalence of atrial fibrillation in the US, driving demand for surgical solutions. AtriCure's specialized portfolio differentiates it in a market dominated by larger players, with US listings providing direct access for American retail investors.

Conclusion

AtriCure's Q1 2026 results showed strong revenue growth and a return to profitability, fueled by product adoption. While shares dipped post-earnings, the company's outlook for 12.8% annual revenue growth to $717.8 million by 2028 underscores its trajectory in cardiac devices. US investors may note its Nasdaq listing and exposure to domestic healthcare demand.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.